Flibanserin May Be Closer to FDA Approval
Erections After Prostate Cancer Surgery
Flibanserin, a drug developed to treat hypoactive sexual desire disorder (HSDD) in women, has been recommended for approval by the U.S. Food and Drug Administration (FDA).
HSDD is a persistent lack of sexual desire accompanied by emotional distress.
On June 4th, an FDA advisory panel voted 18-6 in favor of the recommendation. However, the decision came with proposed conditions.
Flibanserin has twice been rejected by the FDA because of safety and effectiveness concerns. Side effects of flibanserin include low blood pressure, dizziness, sleepiness, and fainting.
With last week's decision, the panel recommended warning labels on flibanserin packaging so that women are aware of the risks. They also suggested that doctors be certified to prescribe the drug.
The FDA is not required to follow advisory panels' recommendations, but often does. The drug could be approved as early as August and would be marketed under the name Addyi.
Please click here for more details.
Testosterone Therapy: Benefits Outweigh Risks, Experts Say
Prostatectomy is a typical treatment for prostate cancer and often a successful one. However, the impact of surgery on a man's sex life can be uncertain.
The prostate is surrounded by nerves that are important for erections. While surgeons do their best to spare these nerves and keep them intact, sometimes erectile problems are unavoidable.
In our latest blog post, we take a closer look at erectile function after prostatectomy. We discuss penile rehabilitation strategies and offer some coping tips for men and their partners. Click here to read more.
Testosterone replacement therapy has more pros than cons, said a panel of experts at the American Association of Clinical Endocrinologists’ 24th Annual Scientific and Clinical Congress, held last month in Nashville.
The treatment has been controversial over the last few years, with some studies raising concerns about increased risk for heart disease and stroke. However, these findings have been questioned by other researchers.
Please click here to learn more about testosterone therapy and the panel's comments.